
BE Ventures Leads AcroCyte Therapeutics’ US$10 Million Financing Round to Accelerate Clinical Translation of the R³CE® Platform and U.S. Expansion
Professor Ying-Chih Chang, Co-founder and CEO of AcroCyte Therapeutics AcroCyte Therapeutics, Inc. announced the completion of a new financing round led by BE Health Ventures,
















